Drug Pipeline – Karyopharm’s pipeline of investigational medicines

Regimen	Indication	Study Name	Early Stage	Mid Stage	Late Stage	Commercial
XPOVIO
w/dexamethasone	Multiple myeloma (penta-refractory)	STORM	Early Stage	Mid Stage	Late Stage	Commercial
w/bortezomib + dexamethasone	Multiple myeloma (2L+)	BOSTON	Early Stage	Mid Stage	Late Stage	Commercial
monotherapy	DLBCL (R/R)	SADAL	Early Stage	Mid Stage	Late Stage	Commercial

SELINEXOR
Pivotal Phase 3s

Regimen	Indication	Study Name	Early Stage	Mid Stage	Late Stage	Commercial
SELINEXOR
w/R-GDP	DLBCL (R/R)	XPORT-DLBCL-030	Early Stage	Mid Stage	Late Stage	Commercial
monotherapy	Endometrial Cancer (maintenance)	SIENDO	Early Stage	Mid Stage	Late Stage	Commercial
monotherapy	Endometrial cancer (maintenance; p53 wild-type)	XPORT-EC-042	Early Stage	Mid Stage	Late Stage	Commercial
w/pomalidomide + dexamethasone	Multiple myeloma (2L+; post anti – CD38)	XPORT-MM-031	Early Stage	Mid Stage	Late Stage	Commercial
w/ruxolitinib	Myelofibrosis (treatment naïve)	SENTRY (XPORT-MF-034)	Early Stage	Mid Stage	Late Stage	Commercial

SELINEXOR
Phase 2s

Regimen	Indication	Study Name	Early Stage	Mid Stage	Late Stage	Commercial
SELINEXOR – Pivotal Phase 3s
monotherapy 4,5 (agreement with SOBI)	Myelofibrosis (treatment naïve)	SENTRY-2 (XPORT-MF-044)	Early Stage	Mid Stage	Late Stage	Commercial
w/standard approved agents	Multiple myeloma (relapsed/refractory)	STOMP	Early Stage	Mid Stage	Late Stage	Commercial

SELINEXOR

Regimen	Indication	Study Name	Early Stage	Mid Stage	Late Stage	Commercial
SELINEXOR – Phase 2s
w/R-GDP	DLBCL (R/R)	XPORT-DLBCL-030	Early Stage	Mid Stage	Late Stage	Commercial
monotherapy	Endometrial Cancer (maintenance)	SIENDO	Early Stage	Mid Stage	Late Stage	Commercial

ELTANEXOR

Regimen	Indication	Study Name	Early Stage	Mid Stage	Late Stage	Commercial
ELTANEXOR
monotherapy	Myelodysplastic neoplasms (relapsed/refractory)	KCP-8602-801	Early Stage	Mid Stage	Late Stage	Commercial

: Hematologic Cancer
: Solid Tumor Cancer